EMAIL THIS PAGE TO A FRIEND

Biology open

MiR-153 targets the nuclear factor-1 family and protects against teratogenic effects of ethanol exposure in fetal neural stem cells.


PMID 25063196

Abstract

Ethanol exposure during pregnancy is an established cause of birth defects, including neurodevelopmental defects. Most adult neurons are produced during the second trimester-equivalent period. The fetal neural stem cells (NSCs) that generate these neurons are an important but poorly understood target for teratogenesis. A cohort of miRNAs, including miR-153, may serve as mediators of teratogenesis. We previously showed that ethanol decreased, while nicotine increased miR-153 expression in NSCs. To understand the role of miR-153 in the etiology of teratology, we first screened fetal cortical NSCs cultured ex vivo, by microarray and quantitative RT-PCR analyses, to identify cell-signaling mRNAs and gene networks as important miR-153 targets. Moreover, miR-153 over-expression prevented neuronal differentiation without altering neuroepithelial cell survival or proliferation. Analysis of 3'UTRs and in utero over-expression of pre-miR-153 in fetal mouse brain identified Nfia (nuclear factor-1A) and its paralog, Nfib, as direct targets of miR-153. In utero ethanol exposure resulted in a predicted expansion of Nfia and Nfib expression in the fetal telencephalon. In turn, miR-153 over-expression prevented, and partly reversed, the effects of ethanol exposure on miR-153 target transcripts. Varenicline, a partial nicotinic acetylcholine receptor agonist that, like nicotine, induces miR-153 expression, also prevented and reversed the effects of ethanol exposure. These data collectively provide evidence for a role for miR-153 in preventing premature NSC differentiation. Moreover, they provide the first evidence in a preclinical model that direct or pharmacological manipulation of miRNAs have the potential to prevent or even reverse effects of a teratogen like ethanol on fetal development.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

N0267
(±)-Nicotine, ≥99% (TLC), liquid
C10H14N2
N3876
(−)-Nicotine, ≥99% (GC), liquid
C10H14N2
36733
(−)-Nicotine, PESTANAL®, analytical standard
C10H14N2
AB5622
Anti-Microtubule-Associated Protein 2 (MAP2) Antibody, Detect Microtubule-Associated Protein 2 (MAP2) using this Anti-Microtubule-Associated Protein 2 (MAP2) Antibody validated for use in ELISA, IC, IH, IH(P) & WB with more than 55 product citations.
HPA003956
Anti-NFIB antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
P0130
Progesterone, ≥99%
C21H30O2
P6149
Progesterone, γ-irradiated, BioXtra, suitable for cell culture
C21H30O2
P3972
Progesterone, meets USP testing specifications
C21H30O2
1568007
Progesterone, United States Pharmacopeia (USP) Reference Standard
C21H30O2
46665
Progesterone, VETRANAL, analytical standard
C21H30O2
PHR1142
Progesterone, Pharmaceutical Secondary Standard; Certified Reference Material
C21H30O2
P3300000
Progesterone, European Pharmacopoeia (EP) Reference Standard
C21H30O2
Y0001666
Progesterone for peak identification, European Pharmacopoeia (EP) Reference Standard
C21H30O2
Y0001665
Progesterone for system suitability, European Pharmacopoeia (EP) Reference Standard
C21H30O2
PZ0004
Varenicline tartrate, ≥98% (HPLC)
C13H13N3 · C4H6O6